Inhaled drug company Alexza Pharmaceuticals has announced the promotions of four executives.
The company has promoted James V. Cassella to Executive VP, Research and Development and Chief Scientific Officer; Darl Moreland to Senior VP, Quality; Mark K. Oki to Senior VP, Finance and Chief Financial Officer; and Edwin S. Kamemoto to VP, Regulatory Affairs.
Alexza resubmitted its NDA for Adasuve inhaled loxapine in June 2012 and recently submitted answers to the Day 120 List of Question related to its MAA.
Read the Alexza press release.
